NDC 63323-236-01 - CEFAZOLIN
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-236
- Requested NDC
- 63323-236-01
- Package NDCs from labels
- 63323-236-01, 63323-236-10
- Manufacturer
- Fresenius Kabi USA, LLC | ACS Dobfar SpA
- Effective date
- 2023-09-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CEFAZOLIN - Fresenius Kabi USA, LLC | ACS Dobfar SpA | Fresenius Kabi USA, LLC | ACS Dobfar SpA | 2023-09-27 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-236-01 | CEFAZOLIN | 2.2 mL in 1 VIAL | POWDER, FOR SOLUTION | 2.2 | 8 | |
| 63323-236-10 | CEFAZOLIN | 25 in 1 CARTON | POWDER, FOR SOLUTION | 25 | 8 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-236-10 | EA - Each | 63323-236 | 145ad34f-e4a0-46d6-aab5-e55a64fba5ad | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CEFAZOLIN SODIUM | ACTIVE INGREDIENT | P380M0454Z | CEFAZOLIN (CEFAZOLIN SODIUM) POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 3 | |
| CEFAZOLIN | ACTIVE MOIETY | IHS69L0Y4T | CEFAZOLIN (CEFAZOLIN SODIUM) POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 3 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | 1999084a-124c-45f9-801f-416a1b942c96 | 2026-06-24 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 26de1ce9-06a9-486f-b27d-2ac635f018d1 | 2026-05-14 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Civica, Inc. | 9ea55207-6d86-401e-b9b9-73c9534a233f | 2026-05-14 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 1dc9de56-e259-4546-a1db-23119a8a088e | 2026-05-14 | Warnings, Adverse reactions | 1665052 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | 4f3a9248-a354-4c77-bf5b-9eed38f00219 | 2026-02-27 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Hospira, Inc | 62441488-fc97-4535-a249-4485fb075022 | 2026-01-21 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | 00dd6da7-50a8-44c9-b2dc-7948973df392 | 2026-01-07 | Warnings, Adverse reactions | ANDA065303 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN SODIUM | Baxter Healthcare Corporation | d91a8d13-99a0-4d87-88dc-71cbd37922b4 | 2025-12-10 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Civica, Inc. | c24e604f-16ca-4945-8e9d-277cc67a8c68 | 2025-11-20 | Warnings, Adverse reactions | P380M0454Z |
| CEFAZOLIN | CEFAZOLIN | Henry Schein, Inc. | 197d5702-2c20-480e-8246-4d0d21f871be | 2025-10-27 | Warnings | 1665050 P380M0454Z |
| CEFAZOLIN | CEFAZOLIN | Henry Schein Inc. | 922fb1a1-ad4c-4a12-8d5d-00fe13af18e8 | 2025-10-27 | Warnings, Adverse reactions | 1665052 P380M0454Z |
| CEFAZOLIN | CEFAZOLIN | Henry Schein, Inc. | 5a8c4bb2-a75e-4d7d-91fb-9a95f04fc94b | 2025-10-27 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | ProPharma Distribution | 3d5cc73c-8a41-b285-e063-6294a90a609f | 2025-08-27 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 570d2583-9ce7-4941-bf7c-6ebc783c0f2b | 2025-07-25 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Apotex Corp. | 0422fe47-c372-494f-bac2-612f550b44a4 | 2025-07-15 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | f17160d4-fc42-4f9c-abb8-d04f01ae6dd1 | 2025-04-07 | Warnings, Adverse reactions | ANDA065303 1665052 1665050 P380M0454Z |
| Cefazolin Sodium | CEFAZOLIN SODIUM | B. Braun Medical Inc. | 17f8f038-c204-4dab-80d7-6f7ac41ddbec | 2025-03-10 | Warnings, Adverse reactions | 1665050 P380M0454Z |
| Cefazolin | CEFAZOLIN | Sandoz Inc | 18e7366a-1b3e-4010-8f4a-dd559d4f2146 | 2025-02-05 | Warnings, Adverse reactions | 1665052 1665050 P380M0454Z |
| CEFAZOLIN | CEFAZOLIN SODIUM | Samson Medical Technologies, L.L.C. | cf13db9c-d8a1-489f-9aa0-fc70839d4bbc | 2025-01-08 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 6c7761d3-c154-4802-9876-627cd42913f0 | 2024-12-31 | Warnings, Adverse reactions | P380M0454Z |